| TOTAL | $16M |
| VENTURE FUNDING TOTAL | $16M |
| Venture Round, 9/10 Sofinnova Ventures InterWest Partners Thomas, McNerney & Partners | $16M |
Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
